Quantitative MRI models of HN Cancers for Physiological Adaption of RT

描述（由申请人提供）：尽管代谢和生理成像已经显示出对放射治疗（RT）结果的预后和预测价值，并可能用于支持治疗修改，但由于生理图像的可重复性、肿瘤中图像参数的异质性以及缺乏支持治疗修改的工具等问题，临床应用具有挑战性。我们假设，鉴于肿瘤的潜在异质性及其对治疗的反应，生理成像可以通过稳健和定量地识别比肿瘤整体成像特征具有更好预测价值的亚体积来最好地用于个体化RT，并且可能是局部失败的部位。这些亚体积可以为辐射剂量再分配提供空间指导，如局部增强，以改善预后。我们已经开发并研究了模糊逻辑模式识别技术，用于从患者和多个时间点的肿瘤血容量（BV）的异质性分布中识别头颈部（HN）癌症的这些亚体积。基于我们的发现，在化疗- rt的早期过程中，治疗前持续存在的HN肿瘤的大的不良灌注亚体积比肿瘤中平均BV的变化更有可能预测局部衰竭，我们将进一步发展亚体积定义方法，将其扩展到扩散加权（DW） MR成像，并在预后不良的HN癌症的随机II期临床试验中评估和验证它。我们的目标是：(1)开发定量和自动化的方法，从动态对比增强（DCE）和DW MRI中提取HN肿瘤的重要亚体积，以预测局部和区域失败；(2)利用测试-重测数据，前瞻性地评估我们的方法提取的亚体积强度和定义的可变性和可重复性；(3)前瞻性评估和验证该方法在一项随机II期临床试验中对局部-区域失败的亚量预测。影响：除非诊所能够有效定量地获取和分析这些图像，并以准确的方式使用预测结果，否则这些强大的成像技术在肿瘤RT中产生有意义的差异的好处可能会完全被掩盖。本项目努力实现这些目标。该项目开发的框架可以转化为其他身体部位以及其他成像方式。通过与一家商业公司合作，我们将为社区中的用户提供这种方法。

DESCRIPTION (provided by applicant): Although metabolic and physiological imaging have shown prognostic and predictive value for radiation therapy (RT) outcome and may serve to support therapy modification, clinical utilization is challenging due to issues such as reproducibility of physiological images, heterogeneity of the image parameters in the tumor, and lack of tools to support therapy modification. We hypothesize that, given the underlying heterogeneity of tumors and their response to treatment, physiological imaging can be best utilized for individualizing RT by robustly and quantitatively identifying subvolumes that have a better predictive value than the imaging characteristics of the tumor as a whole, and are the likely sites of local failure. These subvolumes can serve spatial guide for radiation dose redistribution such as focal boosting to improve outcomes. We have developed and investigated fuzzy logic pattern recognition techniques for identifying these subvolumes of head-and-neck (HN) cancer from heterogeneous distributions of tumor blood volume (BV) across patients and over multiple time points. Based on our findings that large poorly-perfused subvolumes of HN tumors before treatment that persist during the early course of chemo-RT have the potential to predict local failure better than the change in the mean BV in the tumor, we will further develop the subvolume definition method, extend it to diffusion- weighted (DW) MR imaging, and evaluate and validate it in a randomized phase II clinical trial of poor- prognosis HN cancers. Our aims are: (1) Develop quantitative and automated methods to extract significant subvolumes of HN tumors from dynamic contrast enhanced (DCE) and DW MRI for prediction of local and regional failure; (2) Prospectively assess variability and reproducibility of the subvolume intensity and definition extracted by our methods using test-retest data; and (3) Prospectively evaluate and validate that the method yields subvolumes predictive of local-regional failure in a randomized phase II trial of radiation dose boosting for poor-prognosis HN cancer. Impact: Unless clinics can acquire and analyze these images effectively and quantitatively, and use predictive results in an accurate fashion, the benefit of these powerful imaging techniques to make a meaningful difference in tumor RT may be completely obscured. This project strives to achieve these goals. The framework developed in the project can be translated into other body sites as well as other imaging modalities. By partnering with a commercial company, we will make this method available for the users in the community.